Nuevolution Enters Lead Discovery Collaboration in the Field of Epigenetic Disorders
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Nuevolution A/S has announced that it has entered into a lead discovery collaboration focused on epigenetic disorders.
A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors. The 24 MDKK budget project is supported by the Danish High Technology Fund.
During the collaboration, Nuevolution will apply its proprietary and powerful Chemetics® technology to screen hundreds of millions small molecules. All biology and disease skills and expertises needed for the project to be successful are provided by EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (BRIC).
“We are delighted with the establishment of this collaboration. We believe that this consortium of skills represents the ideal combination to efficiently identify and develop novel drug leads toward epigenetic based disorders,” said Alex Gouliaev, CEO of Nuevolution A/S. “It is with great pleasure we apply our Chemetics® technology within the exciting area of epigenetics and we are looking forward to a successful collaboration”.
A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors. The 24 MDKK budget project is supported by the Danish High Technology Fund.
During the collaboration, Nuevolution will apply its proprietary and powerful Chemetics® technology to screen hundreds of millions small molecules. All biology and disease skills and expertises needed for the project to be successful are provided by EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (BRIC).
“We are delighted with the establishment of this collaboration. We believe that this consortium of skills represents the ideal combination to efficiently identify and develop novel drug leads toward epigenetic based disorders,” said Alex Gouliaev, CEO of Nuevolution A/S. “It is with great pleasure we apply our Chemetics® technology within the exciting area of epigenetics and we are looking forward to a successful collaboration”.
